Search Results

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, regulators and many others speak out.

During the first quarter, 22 rounds of biopharma layoffs in California affected about 995 employees total, while 17 rounds in Massachusetts impacted around 410 people, based on BioSpace estimates. Meanwhile, competition for jobs in those states increased year over year, according to BioSpace data.

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals lost their jobs in the first quarter.

Swedish Orphan Biovitrum AB and CTI BioPharma Corp. announced the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp..

Over 80% of those living outside of biopharma’s biggest hubs, like San Diego or Boston, have a tough time finding work, according to a BioSpace LinkedIn poll. Biopharma professionals in Oregon and Connecticut and a BioSpace recruitment manager share their insights on this issue.

Biopharma employees reporting a positive business outlook for their companies dropped month over month but increased year over year in February, according to the Glassdoor Employee Confidence Index. Glassdoor’s findings align with recent BioSpace data.

Nearly half of BioSpace poll respondents recently took a biopharma job they were overqualified for, a finding that didn’t surprise a talent acquisition expert, who said it’s become much more likely to happen.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

CTI BioPharma announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB, a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion.